CJ BioscienceCJ 바이오사이언스
311690 · KOSDAQ · ₩311690 · CJ 바이오사이언스
₩3,690▲ ₩40 (1.10%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.7B | ₩3.5B | ₩5.6B | ₩4.1B | ₩4.4B |
| Cost of sales | ₩3B | ₩3.1B | ₩3.7B | ₩2.7B | ₩2.7B |
| Gross profit | ₩699M | ₩365M | ₩1.8B | ₩1.4B | ₩1.7B |
| Operating income | −₩25B | −₩34B | −₩32B | −₩33B | −₩10B |
| Net income | −₩24B | −₩33B | −₩23B | −₩35B | −₩19B |
| Net income to shareholders | −₩24B | −₩33B | −₩23B | −₩35B | −₩19B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩72B | ₩100B | ₩91B | ₩91B | ₩116B |
| Current assets | ₩52B | ₩77B | ₩65B | ₩51B | ₩82B |
| Cash and equivalents | ₩10B | ₩8.3B | ₩64B | ₩49B | ₩62B |
| Total liabilities | ₩19B | ₩22B | ₩20B | ₩42B | ₩29B |
| Current liabilities | ₩15B | ₩19B | ₩15B | ₩35B | ₩24B |
| Borrowings | ₩7B | ₩6.4B | ₩4B | ₩24B | ₩18B |
| Total equity | ₩54B | ₩78B | ₩71B | ₩50B | ₩88B |
| Shareholders' equity | ₩54B | ₩78B | ₩71B | ₩50B | ₩88B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩23B | −₩28B | −₩25B | −₩21B | −₩8.4B |
| Capital spending | ₩11M | ₩378M | ₩4.9B | — | — |
| Free cash flow | −₩23B | −₩28B | −₩30B | −₩21B | −₩8.4B |
Consolidated where available. Amounts in won.
Also known as: CJ Bioscience / CJ 바이오사이언스 / 311690 / KRX:311690
Source: KRX statistical information